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Market access and coverage policies for health technologies should ideally be based on 
clinical trials that assess final outcomes relevant to patients, such as survival, morbidity, 
and health-related quality of life. Nevertheless, growing pressure for faster access to 
innovative treatments for patients in the past two decades has led to the introduction of 
various regulatory initiatives intended to facilitate this1. Consequently, regulatory 
authorities and payers often have to base their decisions about the use of a technology 
on surrogate outcomes, which allow trials to be done less expensively with fewer 
patients in a relatively short period. For example, more than 40% of trials used as the 
basis for approval of new indications by the US Food and Drug Administration (FDA) 
between 2005 and 2012 had a primary outcome that was a surrogate endpoint2. 
Furthermore, evidence from surrogate endpoints may not only expedite the regulatory 
approval of new health technologies but also inform coverage and reimbursement 
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decisions. Over the last decade, between 27 to 50% of submissions to the National 
Institute for Health and Care Excellence (NICE) in the United Kingdom, the 
Pharmaceutical Benefits and Advisory Committee in Australia, and the Common Drug 
Review in Canada were based on surrogate endpoints3. 
 
However, relying on surrogate endpoints can pose several serious problems for 
healthcare decision-makers. First, surrogate endpoints may not capture the combined 
risk–benefit profile of a health technology4. Some drugs approved on the basis of 
surrogate endpoints have subsequently been associated with serious safety problems 
and have had to be withdrawn from the market or have their indications substantially 
restricted. Even if the surrogate lies in the only causal pathway of the disease process, 
reliance on surrogate endpoints can often lead to overestimation of the magnitude of the 
treatment effect on the final endpoint5.  
 
Second, the use of surrogate endpoint data requires decision-makers to extrapolate 
beyond the observed findings in order to estimate the expected true benefits to patients 
and health systems. Thus, clinical superiority on a surrogate endpoint may not 
necessarily translate into benefits that are good value for money for healthcare systems. 
This can be illustrated by the example of dasatinib, which has been approved by the 
European Medicines Agency for the treatment of chronic myeloid leukaemia. This 
approval was based on trial showing superior confirmed complete cytogenetic response 
by 12 months for dasatinib versus imatinib (77% versus 66%, p=0·007)6. However, an 
assessment of the drug by the National Institute of Health and Care Excellence (NICE) 
concluded that the estimated incremental gain in survival (22·7 years versus 21·3 
years) extrapolated from the observed improvement on the surrogate endpoint came at 
a patient cost in excess of €200,000 per quality adjusted life years. As a result of this 
assessment, NICE did not recommend coverage of the drug6.  
 
In order for regulatory authorities and payers to use a surrogate endpoint with 
confidence, a validation process for such endpoints is needed. Here, we present a 
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three-step framework for the validation and appropriate use of surrogate endpoints in 
both licensing and coverage or reimbursement decisions (FIG. 1).  
 
Establish the level of evidence. The first step is to consider the hierarchy of available 
evidence7. The biological plausibility of the relationship between the surrogate endpoint 
and final outcome is necessary but not sufficient. Evidence is considered to be ‘level 2’ 
when a strong correlation exists between the surrogate and the final endpoint across 
cohorts or at the level of the individual patient. However, individual patient correlations 
do not provide the highest level of evidence in order to validate surrogate measures, 
although they may identify good prognostic markers8. ‘Level 1’ evidence requires 
demonstration of the relationship between the treatment effect on the surrogate 
endpoint and the final outcomes, preferably across multiple randomised trials. Trial-
based evidence of a final outcome is usually not available for a new healthcare 
technology for which surrogates are used, so this evidence needs to be sourced from 
other trials of the same or a similar technology — for example, trials should be of drugs 
from the same class or, if such evidence is not is available, drugs from a different class.  
 
Assess the strength of the association. The second step is to assess the strength of 
the association between the surrogate endpoint and the final outcome. Among several 
approaches to address this issue, regression-based and meta-analytic approaches 
dominate the field. The most reliable approach is to perform a meta-analysis using 
patient-level data from all randomised trials of this treatment9. When patient-level data 
are available, two levels of association can be estimated: the association between the 
surrogate and the final outcome, and the association between the effect of treatment on 
the surrogate and the final outcome. Thresholds set to identify good surrogates can be 
as high as 0·8 for correlation coefficients (ρ) or 0·65 for coefficients of determination 
(R2), which are particularly strict rules for the acceptability of putative surrogate 
endpoints when applied in practice10.  
 
Quantify the relationship between the surrogate and the final outcome. The final 
step relates to predicting and quantifying the effect on the final outcome based on the 
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observed effect on the surrogate. A quantitative approach has been proposed that 
consists of estimating the ‘Surrogate Threshold Effect’ (STE), which is the magnitude of 
treatment effect on the surrogate that would predict a significant treatment effect on the 
final outcome11. This is crucial for decisions on coverage and reimbursement. 
Regulators usually focus on early evidence of safety and efficacy to determine if the 
balance of benefits and risk is positive when informing the design of registration trials, 
while reimbursement agencies usually consider long-term effectiveness or cost-
effectiveness. Whether decisions on market access and reimbursement are based on a 
formal economic evaluation or on the magnitude of the clinical benefit, the effect of the 
treatment on the surrogate endpoint needs to be large enough to predict an 
improvement in the final outcome of interest before the technology can be concluded to 
be cost-effective.  
 
To date, few empirical assessments have investigated the adequacy of evidence for 
specific surrogate endpoints or groups of surrogates, particularly in terms of 
reimbursement policy. One exception is oncology, for which there is a long tradition of 
using surrogates. With few exceptions, such as metastatic colorectal or ovarian cancer, 
the strength of the associations between the surrogate and final outcomes tended to be 
relatively low in studies so far.   
 
In conclusion, surrogates can result in market access for technologies that turn out to 
offer no true health benefit—or even harm—to patients and can result in overestimation 
of treatment effects (and economic value), which can lead to inappropriate decisions on 
coverage. However, the use of appropriately validated surrogate endpoints within a 
consistent framework provides an important potential to speed up access to innovative 
technologies that offer important value for patients and healthcare systems and to 
improve efficiency and equity within the research and development environment.  
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Figure 1 | Framework for validation of surrogate endpoints: case study of anti-
hypertensives. The graph shows the sequence of actions to implement in a health 
technology assessment of a drug technology when surrogate outcomes evidence 
is available. After an initial scope of the decision problem, the first step requires 
systematic review of the evidence explaining the relationship between the 
surrogate outcome and the final patient relevant outcome (establish the level of 
evidence). This evidence will then be assessed to define whether the surrogate is 
associated with and predictive of the final patient relevant outcome (validation). If 
so, a quantification of the estimated effect on the final outcome given the 
observed effect on the surrogate outcome in the setting of interest will be 
performed (quantification), and could be used as input in a cost-effectiveness 
analysis. 
 
 
QALY, quality-adjusted life-year; RCT, randomised controlled trial. 
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